Floatz logo

Mesna

Reticular Dysgenesis

Masonic Cancer Center, University of MinnesotaSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Reticular Dysgenesis cohort.

Asset / SponsorPhaseRating
Evomela
Masonic Cancer Center, University of Minnesota
N/AD
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Masonic Cancer Center, University of Minnesota
N/AD
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
N/AD
Busulphan
Masonic Cancer Center, University of Minnesota
N/AD
Fludarabine
Masonic Cancer Center, University of Minnesota
N/AD

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
69 / 100
View asset →
NK/T-cell LymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →